AZN
AstraZeneca PLC
NYSE · Healthcare · Drug Manufacturers - General · GB
$163.95
−0.88%Year over year
Reported trailing growth
- Revenue
- +8.6%
- EBITDA
- +22.4%
- EBIT
- +23.4%
- EPS
- -26.3%
- Free cash flow
- +6.8%
- Operating cash flow
- +3.1%
Forward estimates
Based on analyst estimates
- Revenue
- +7.6%
- EBITDA
- +61.2%
- EPS
- +62.6%
Three-year CAGR
- Revenue
- +9.8%
- EBITDA
- +29.7%
- EBIT
- +54.1%
- Net income
- +46.1%
- EPS
- +46.0%
- Free cash flow
- +6.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026